Overview

Generic Name(s):
dactinomycin
Trade Name(s):
Lyovac Cosmegen and Cosmegen
NCI Definition [1]:
A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)

Dactinomycin has been investigated in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials investigating dactinomycin, 3 are phase 2 (3 open) and 2 are phase 3 (2 open).

PAX3-FOXO1 Fusion is the most frequent biomarker inclusion criterion for dactinomycin clinical trials.

Alveolar rhabdomyosarcoma, embryonal rhabdomyosarcoma, and rhabdomyosarcoma are the most common diseases being investigated in dactinomycin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dactinomycin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dactinomycin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
meractinomycin, lyovac cosmegen, dactinomycine, dactinomycin, dactinomycin, dact, actinomycin-[thr-val-pro-sar-meval], actinomycin x 1, actinomycin iv, actinomycin i1, actinomycin d, actinomycin d, meractinomycin, actinomycin c1, actinomycin a iv, 2-bis[cyclo(n-methyl-l-valyl-sarcosyl-l-prolyl-d-valyl-l-threonyl)]-1,9 dimethyl-4,6 3h-phenoxazinone-3, Lyovac Cosmegen, Cosmegen
Drug Categories [2]:
Antitumor antibiotics
NCIT ID [1]:
C412

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.